ONE EYE VITAMIN DOES NOT FIT ALL
The US National Eye Institute has conducted two long-term Age-Related Eye Disease Studies (AREDS and AREDS2) showing that high-dose eye vitamin formulations including antioxidants (vitamin C, vitamin E) and zinc can protect a significant nubmer of patients from developing advanced Age-Related Macular Degeneration (AMD).
In a recent analysis of the 12-year AREDS data, researchers investigated whether a patient's specific AMD genes influenced the safety and efficacy of ingredients in these high-dose formulations.
It was found that different components in these eye formulations are good for some, but bad for others. For example, patients with specific AMD risk genes, zinc provided the most protective effect; but in patients with other AMD risk genes, zinc could cause harm and accelerate vision loss. Similar effects were seen in patients with other genes who were treated with high-dose vitamins C and E.
HOW DO YOU FIND OUT WHICH EYE VITAMIN IS RIGHT FOR YOU?
Vita Risk™ is a DNA test that shows which eye vitamin formulations may be helpful or harmful to patients diagnosed with Intermediate AMD based on their genetic makeup. The doctor needs to know the patient's genetic profile in order to prescribe the safest and most effective eye vitamin formulation.
THE ANSWER IS IN THE VITA RISK RESULT
The illustration below shows the three different patient genetic profiles (the combination of ARMS2 and CFH genes). The vertical (Y) axis on the graph shows estimated likelihood of developing Advanced AMD with vision loss for each of the different treatments shown below. the horizontal (X) axis shows time up to 12 years.
WHAT IS INVOLVED IN TAKING THE VITA RISK TEST?
The Vita Risk test is a simple cheek swab taken in your eye doctor's office. Results will be returned to your doctor within a few weeks.
WHAT IS YOUR GENETIC RISK?
Age-Related Macular Degeneration (AMD) is the leading cause of severe vision loss and blindness in people over the age of 50. This progressive disease can destroy central vision, impairing the ability to perform everyday tasks such as reading, driving or watching television. The incidence of AMD grows from 1 in 10 people over the age of 60 to more than 1 in 4 people over the age of 75. Early detection and treatment of AMD is critical for the prevention of blindness.
Genetics account for over 60% of the risk of developing AMD. When you are tested, you and your eye doctor will know your genetic risk. Knowing this information will allow your doctor to recommend the best personalized treatment for you to reduce your risk of vision loss from this disease.
Components of this DNA test are shown below:
PATIENTS: If you are taking eye vitamins for AMD or you think that you or your family members may be at risk for AMD, talk to your eye doctor and discuss whether this test is right for you.